The Federal Trade Commission says Abbott Laboratories (ABT) can proceed with its proposed $25 billion acquisition of St. Jude Medical (STJ) . As a result of the green light, Abbott will sell two medical device units to Tokyo-based Terumo for $1.2 billion. The merger of Abbot and St. Jude was cleared by European antitrust regulators back in November, provided that U.S. regulators were on board with the transaction.

More from Video

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Why Starbucks Latest Data Reveal Should Worry Investors

Why Starbucks Latest Data Reveal Should Worry Investors

Buick's $40,000 Tough-Looking Station Wagon Is a Worthy Driveway Addition

Buick's $40,000 Tough-Looking Station Wagon Is a Worthy Driveway Addition

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks